Candidate biomarkers in psychiatric disorders: state of the field
The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can
aid in objectively diagnosing patients and providing individualized treatment …
aid in objectively diagnosing patients and providing individualized treatment …
Dopamine receptor subtypes, physiology and pharmacology: new ligands and concepts in schizophrenia
JC Martel, S Gatti McArthur - Frontiers in pharmacology, 2020 - frontiersin.org
Dopamine receptors are widely distributed within the brain where they play critical
modulator roles on motor functions, motivation and drive, as well as cognition. The …
modulator roles on motor functions, motivation and drive, as well as cognition. The …
Artificial intelligence in psychiatry research, diagnosis, and therapy
J Sun, QX Dong, SW Wang, YB Zheng, XX Liu… - Asian Journal of …, 2023 - Elsevier
Psychiatric disorders are now responsible for the largest proportion of the global burden of
disease, and even more challenges have been seen during the COVID-19 pandemic …
disease, and even more challenges have been seen during the COVID-19 pandemic …
[HTML][HTML] NeuroMark: An automated and adaptive ICA based pipeline to identify reproducible fMRI markers of brain disorders
Many mental illnesses share overlapping or similar clinical symptoms, confounding the
diagnosis. It is important to systematically characterize the degree to which unique and …
diagnosis. It is important to systematically characterize the degree to which unique and …
Cognitive impairment associated with schizophrenia: from pathophysiology to treatment
DC Javitt - Annual Review of Pharmacology and Toxicology, 2023 - annualreviews.org
Cognitive impairment is a core feature of schizophrenia and a major contributor to poor
functional outcomes. Methods for assessment of cognitive dysfunction in schizophrenia are …
functional outcomes. Methods for assessment of cognitive dysfunction in schizophrenia are …
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics
Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …
negative and cognitive symptoms of schizophrenia, and are ineffective—with the exception …
Artificial intelligence applications in psychoradiology
One important challenge in psychiatric research is to translate findings from brain imaging
research studies that identified brain alterations in patient groups into an accurate diagnosis …
research studies that identified brain alterations in patient groups into an accurate diagnosis …
Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction
F Guan, T Ni, W Zhu, LK Williams, LB Cui, M Li… - Molecular …, 2022 - nature.com
Schizophrenia (SCZ) is a debilitating neuropsychiatric disorder with high heritability and
complex inheritance. In the past decade, successful identification of numerous susceptibility …
complex inheritance. In the past decade, successful identification of numerous susceptibility …
AI in patient flow: applications of artificial intelligence to improve patient flow in NHS acute mental health inpatient units
FM Dawoodbhoy, J Delaney, P Cecula, J Yu, I Peacock… - Heliyon, 2021 - cell.com
Introduction Growing demand for mental health services, coupled with funding and resource
limitations, creates an opportunity for novel technological solutions including artificial …
limitations, creates an opportunity for novel technological solutions including artificial …
Neuroimaging and multiomics reveal cross-scale circuit abnormalities in schizophrenia
Schizophrenia (SCZ) is a highly heterogeneous disorder with diverse clinical manifestations
and macro-and microscale biological variations, usually observed at dissociable levels …
and macro-and microscale biological variations, usually observed at dissociable levels …